VJRegenMed is committed to improving our service to you

Share this video  

VJRegenMed is committed to improving our service to you

Advanced Therapies Week 2022 | Optimizing patient access and development costs of gene therapies

Will Chou, MD, Aruvant, New York, NY, discusses strategies to lower production costs and increase patient access to novel gene therapies. Manufacturing therapies is the biggest factor in determining cost and investing in new technologies as well as increased demand will incentivize innovation and streamline the production process. Increased research on experimental therapies have increased patient access to them and developing unique features that will provide value to the product will additionally help patients to obtain novel therapies. This interview took place at Advanced Therapies Week 2022.

Disclosures

Will Chou, MD, is an employee of Aruvant.